胶质母细胞瘤的代谢与翻译后脆弱性:二硫死亡、糖基化及对 CAR-T 治疗的启示
Metabolic and Post-Translational Vulnerabilities of Glioblastoma: Disulfidptosis, Glycosylation, and Implications for CAR-T Therapy.
MODALITY HUB
FOR TREATMENT
现在就能报名的(招募中)排在最前,共 0 项。同一状态内中国中心优先。信息来自 ClinicalTrials.gov 与 CDE 公开登记。能否入组、费用与可及性,以登记原文和主治医生判断为准。
FOR RESEARCH
Metabolic and Post-Translational Vulnerabilities of Glioblastoma: Disulfidptosis, Glycosylation, and Implications for CAR-T Therapy.
Natural killer cell dysfunction in glioma: from immune evasion to immunotherapy.
Locoregional and systemic adoptive cellular therapies for pediatric brain tumors: a systematic review of CAR‑T, TCR‑engineered T cells, and NK cell st
Specific and safe targeting of glioblastoma using switchable and logic-gated RevCAR T cells.
Challenges and breakthroughs: current landscape and future prospects of CAR-T cell therapy clinical trials for solid tumors.
Clinical progress in the development of CAR T cells to treat malignant glioma.
在研 CAR-T 细胞疗法的快速演进预示着胶质瘤治疗未来的巨大潜力。
MEMBER ACCOUNT
登录成功会直接打开下一页。